MDGL NASDAQ
Madrigal Pharmaceuticals, Inc.
1W: -5.8%
1M: -14.8%
3M: -19.5%
YTD: -25.9%
1Y: +4.5%
3Y: +234.8%
5Y: +446.5%
$440.33
+2.59 (+0.59%)
Weekly Expected Move ±4.1%
$399
$416
$434
$452
$470
Credit Risk of going bust: lower than 79% of companies Debt: 3.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.39 (down 99.7%), Madrigal Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $347.8M against a stock market value of $10.17B.
Distance to default 9.47 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $171.4M (short-term plus half of long-term), stock volatility 43.5%; Altman Z'' -2.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $1.39 (down 99.7%), Madrigal Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $347.8M against a stock market value of $10.17B.
Distance to default 9.47 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $171.4M (short-term plus half of long-term), stock volatility 43.5%; Altman Z'' -2.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
Engineers Gate Manager LP Makes New $709,000 Investment in Madrigal Pharmaceuticals, Inc. $MDGL
Bank of America Corp DE Purchases Shares of 134,036 Madrigal Pharmaceuticals, Inc. $MDGL
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 1,800 Madrigal Pharmaceuticals, Inc. $MDGL
Goldman rebalances its long duration stock basket
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
Corient Private Wealth LP Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL
Ten healthcare stocks leading in year-over-year CapEx growth
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of “Moderate Buy” by Analysts
Bamco Inc. NY Makes New $2.42 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
Allworth Financial LP Buys New Position in Madrigal Pharmaceuticals, Inc. $MDGL
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
Madrigal outlines 2027 F4c outcomes readout while reinforcing mid- to high 30s 2026 gross-to-net outlook
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates
Madrigal Pharmaceuticals GAAP EPS of -$1.99 beats by $0.65, revenue of $364.3M beats by $11.13M
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
3 Under-the-Radar Stocks to Buy and Hold
BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL)
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Earnings Scheduled For May 6, 2026
Madrigal sees 2026 gross-to-net in the mid- to high 30s while advancing F4c outcomes readout expected in 2027
Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Madrigal (MDGL) Q1 2026 Earnings Transcript
Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates
Madrigal Pharmaceuticals, Inc. GAAP EPS of -$3.25 beats by $0.79, revenue of $311.3M beats by $10.38M
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals Q1 2026 Earnings Preview
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Calamos Advisors LLC Boosts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Passes Above 200 Day Moving Average – Here’s Why
Altimmune Catalysts: 2026 Data Readouts and Financing Risks
ALT Stock: What Pemvidutide Means for MASH, AUD and ALD
Is Altimmune a Buy Before Phase III MASH Starts in 2026?
Most shorted large cap stocks as of mid-April
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
Capricorn Fund Managers Ltd Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Trump may impose tariffs on drugmakers who haven't signed MFN deals - reports
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of “Moderate Buy” by Analysts
Tango Therapeutics is the best performing healthcare stock in March
Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
Stocks to watch after market on Thursday: MDGL, M, MODD
Madrigal Pharmaceuticals gains amid renewed takeover speculation
Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
ALT Pemvidutide Explained: What Makes It Different in MASH
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
Worst-performing AI-linked large-cap stocks across cloud, chips, and robotics so far in 2026
2,600 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Bamco Inc. NY
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by ArrowMark Colorado Holdings LLC
32,662 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Ally Bridge Group NY LLC
120,000 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Purchased by Alkeon Capital Management LLC
Avoro Capital Advisors LLC Cuts Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
Barclays PLC Cuts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
B. Metzler seel. Sohn & Co. AG Purchases New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
2 Under-the-Radar Stocks to Buy and Hold
Mardi Dier Sells 1,982 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Analysts
American Century Companies Inc. Has $75.96 Million Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL
Artisan Partners Limited Partnership Acquires 4,683 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Earnings Miss
Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday
MDGL Strengthens MASH Franchise With New Genetic Approaches
Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Ribo und Ribocure geben exklusive globale Lizenzvereinbarung mit Madrigal für neuartige siRNA-Therapeutika gegen MASH bekannt
Ribo et Ribocure annoncent un accord de licence mondial exclusif avec Madrigal pour de nouvelles thérapies pARNi ciblant la stéatohépatite associée à un dysfonctionnement métabolique (MASH)
Baader Bank Aktiengesellschaft Invests $885,000 in Madrigal Pharmaceuticals, Inc. $MDGL
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
STVN or MDGL: Which Is the Better Value Stock Right Now?
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Emerald Advisers LLC Sells 2,371 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals (NASDAQ:MDGL) General Counsel Shannon Kelley Sells 692 Shares of Stock
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MDGL Secures Exclusive Global Right for MASH Treatment From PFE
Gladstone Institutional Advisory LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead
Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data
Head to Head Survey: Madrigal Pharmaceuticals (NASDAQ:MDGL) vs. Metagenomi (NASDAQ:MGX)